Dexcom Inc

NASDAQ:DXCMUnited States

Jun 20, 2024

Show headlines and story abstract

• Dexcom Expands AID Partnership Into The Netherlands, from 7:15AM ET on Thursday Jun 20, 2024 by Business Wire

  7:15AM ET on Thursday Jun 20, 2024 by Business Wire
  Companies Mentioned: DXCM

  DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod(R) 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier(1-3)diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,000 children affected*, making it the most common autoimmune disease among children after asthma(4). Type 1 diabetes can be challenging for anyone to manage and live with, but for children with Type 1, and their families, everyday activities such as exercising, eating, and swimming can be even more challenging. The Omnipod(R) 5 tubeless insulin pump integrated with the Dexcom G6 CGM can simplify their lives by offering easier(1-2,4)diabetes management whilst allowing families, friends, and carers to remotely check glucose levels with the unique to Dexcom 'Follow' app||.

• Dexcom Expands AID Partnership Into The Netherlands, from 7:15AM ET on Thursday Jun 20, 2024 by Dow Jones

  7:15AM ET on Thursday Jun 20, 2024 by Dow Jones
  Companies Mentioned: DXCM
  -- The world's most connected continuous glucose monitoring system++, Dexcom G6, now connects with the Omnipod(R) 5 Automated Insulin Delivery (AID) System in The Netherlands. EDINBURGH, Scotland--(BUSINESS WIRE)--June 20, 2024--
  

• Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes, from 6:05AM ET on Thursday Jun 20, 2024 by Business Wire

  6:05AM ET on Thursday Jun 20, 2024 by Business Wire
  Companies Mentioned: DXCM

  DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21-24, 2024, in Orlando.

• Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes, from 6:05AM ET on Thursday Jun 20, 2024 by Dow Jones

  6:05AM ET on Thursday Jun 20, 2024 by Dow Jones
  Companies Mentioned: DXCM
  -- Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. -- ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.1,2 -- New Dexcom G7 automated insulin delivery integrations* further solidify the company's undisputed leadership in CGM connectivity. -- Recently released Dexcom G7 app updates, including Direct to Apple Watch, demonstrate relentless commitment to innovation and improving user experience. SAN DIEGO--(BUSINESS WIRE)--June 20, 2024--